Get started
JOHNSON DRNJOHNSON DRNJOHNSON DRN

JOHNSON DRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

JNJB34 trade ideas

Johnson & Johnson (JNJ) - Approaching the Reversal ZoneIn April, we anticipated a pullback for JNJ, and since then, the stock has dropped approximately 7%, aligning with our expectations. The current trend suggests further downward movement, reinforcing our previous analysis. We are focusing on the support zone ranging from $134 to $116, with a potential lower bound at $109, the Corona-Low. The ongoing pullback could represent the completion of Wave (4) within this target zone, aligning with multiple levels. We are going to be monitoring this for signs of a reversal within this zone. This zone will be crucial to confirm the next possible upward movement.
NYSE:JNJLong
by freeguy_by_wmc
1
Ichimoku Watch: Johnson & Johnson Eyeing Possible Breakout Upcoming Earnings: Johnson & Johnson (ticker: JNJ) is scheduled to report earnings before the market opens today. The consensus Earnings Per Share (EPS) estimate for the fiscal quarter ending June 2024 is $2.71. The reported EPS for the same quarter last year was $2.80. Breakout Above Cloud? The daily chart of Johnson & Johnson shows that this stock has been working with a downtrend since forging an all-time high of $186.69. However, price has struggled to get through $145.00 support since October 2023 and we have recently seen price drive into the upper boundary of the Ichimoku Cloud, made up of the Leading Span B (light orange at $149.30) and the Leading Span A (light green at $147.60). A price break above the upper limit of the Ichimoku Cloud would be considered a bullish signal. Adding weight to a possible move higher is the Conversion Line (blue at $147.80) crossing above the Base Line (red at $147.50) on 11 July, and price movement trading below its Lagging Span (green at $151.01). Price Direction? With the Ichimoku Indicator suggesting a possible breakout higher beyond the Ichimoku Cloud, this could trigger a wave of follow-through buying towards the May top of $154.86.
NYSE:JNJLong
by FPMarkets
Johnson & Johnson Downtrend Line Breakout at $148.9 17.07.2024- Johnson & Johnson chart shows a downtrendline breakout at $148.95 - If breakout holds, price could rally to $152.00; if $152.00 is breached, target $154.40. - If breakout fails, price may drop to $145.06; if $145.06 is breached, target $140.12. Apply risk management Risk Warning: Trading in CFDs is highly speculative and carries a high level of risk. It is possible to lose all of your invested capital. These products may not be suitable for everyone, and you should ensure that you fully understand the risks taking into consideration your investment objectives, level of experience, personal circumstances as well as personal resources. Speculate only with funds that you can afford to lose. Seek independent advice if necessary. Please refer to our Risk Disclosure. BDSwiss is a trading name of BDS Markets and BDS Ltd. BDS Markets is a company incorporated under the laws of the Republic of Mauritius and is authorized and regulated by the Financial Services Commission of Mauritius ( FSC ) under license number C116016172, address: 6th Floor, Tower 1, Nexteracom Building 72201 Ebene. BDS Ltd is authorized and regulated by the Financial Services Authority Seychelles (FSA) under license number SD047, address: Suite 3, Global Village, Jivan’s Complex, Mont Fleuri, Mahe, Seychelles. Payment transactions are managed by BDS Markets (Registration number: 143350) Disclaimer
NYSE:JNJLong
by Stuart_Cowell
JNJ impending shortThe chart illustrates the possibility of a correction down to a major trend line. This would mean millions of dollars lost in market cap within the next several months or years. If the movement is drastic we may see the company attempt perform countermeasures to provide shareholders a soft landing. One of these countermeasures could be (which I think will be more than likely) layoffs, or termination of complete organizations within the company. As technology advances and consumers of JNJ products increase in cost, the company may pivot to less expensive methods of operations. Attrition is a key variable that I foresee in the near future which could help the company regain some stability in the market. Many people will lose their jobs, but shareholder interest is at the forefront of any good company. Skills are easy to obtain nowadays but public moral is probably at an all time low or leveled with 1950s Vietnam era. If people are unmotivated to learn, they will contribute to the overall downturn of the economy.
NYSE:JNJShort
by EJSM
J&J Entangled in Talc-Related Lawsuits and Bankruptcy AllegationCore Issues: * J&J faces numerous lawsuits alleging its talc products contain asbestos and cause cancer. * The company's utilization of a "Texas two-step" bankruptcy strategy to shield assets from litigation has drawn accusations of fraud. Recent Developments: * Cancer victims filed a class action lawsuit on May 22nd, 2024, alleging J&J's fraudulent use of bankruptcy and asset transfers to avoid compensation. * J&J maintains the safety of its talc and claims the lawsuit disrupts their proposed settlement plan. Broader Implications: * This legal battle raises concerns about potential abuses of bankruptcy laws by corporations seeking to evade product liability. * The case has significant financial ramifications for J&J, with analysts citing negative impacts on stock valuation. Conclusion: * The outcome of these lawsuits will determine compensation for victims, J&J's future financial liabilities, and potentially set precedents for corporate responses to mass tort claims. * Upcoming developments, such as the claimant's vote on the settlement and the court's response to the latest bankruptcy filing, will be crucial in resolving this protracted dispute.
NYSE:JNJShort
by signalmastermind
Johnson & Johnson's Q1 Triumph: Surpassing ExpectationsJohnson & Johnson (NYSE: NYSE:JNJ ) has kicked off 2024 with a resounding victory, showcasing robust first-quarter earnings that outpaced Wall Street estimates and signaling a promising trajectory for the rest of the year. The pharmaceutical giant reported an impressive adjusted EPS of $2.71, marking a remarkable 12.4% surge compared to the previous year. This stellar performance surpassed analysts' projections of $2.64, underscoring the company's resilience and strategic prowess. In terms of revenue, Johnson & Johnson ( NYSE:JNJ ) posted sales of $21.38 billion, reflecting a steady 2.3% increase year over year. While this figure nearly mirrored market expectations, the operational growth of 3.9% and adjusted operational growth of 4.0% underscored the company's underlying strength and adaptability in navigating market dynamics. One of the standout performers in Johnson & Johnson's portfolio was its Innovative Medicine segment, which witnessed robust operational sales growth of 8.3% to reach $13.6 billion. Notably, sales of key drugs such as Stelara and Darzalex demonstrated resilience, with the latter experiencing a notable 19% surge in revenue. Moreover, the company's medical devices business proved to be a significant driver of growth, generating sales of $7.82 billion during the quarter, marking a commendable 4.5% year-over-year increase. This uptick was fueled by strong performances in electrophysiology products and cardiovascular solutions, showcasing Johnson & Johnson's ( NYSE:JNJ ) diverse revenue streams and market leadership in healthcare innovation. In a move sure to delight investors, Johnson & Johnson ( NYSE:JNJ ) announced a 4.2% increase in its quarterly dividend, a testament to its commitment to delivering value to shareholders amidst a challenging economic landscape. Looking ahead, Johnson & Johnson ( NYSE:JNJ ) raised its fiscal year 2024 guidance, projecting operational sales in the range of $88.7 billion to $89.1 billion and adjusted EPS between $10.57 and $10.72. This optimistic outlook, coupled with the company's track record of delivering on its promises, instills confidence in its ability to navigate future opportunities and challenges. Despite a slight dip in premarket trading following the earnings release, Johnson & Johnson's ( NYSE:JNJ ) strong performance in Q1 sets a solid foundation for continued success, reaffirming its position as a leader in the healthcare industry and a reliable investment choice for shareholders worldwide.
NYSE:JNJ
by DEXWireNews
JOHNSON & JOHNSON Time to start buying.Johnson & Johnson (JNJ) quickly hit the $147.00 Target that we set on our very recent sell call (April 03, see chart below) and is now approaching the bottom of the massive 2-year Channel Down: Even though based on the very reliable and consistent Sine Waves, the bottom might be a process that can take up to 2-months, the stock is low enough for medium-term investors to start considering adding buys. On top of that, the 1D RSI is highly oversold below 20.00, the lowest it has been in more than 4 years (since February 28 2020)! As a result and since the Bearish Legs of this Channel Down have ranged within -14.78% and -17.58%, we are turning bullish on this stock, targeting $157.50 (minimum +13.00% rise as with January 22 2024 High). ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJLong
by TradingShot
Johnson & Johnson (JNJ): Navigating a Constricted MarketExecutive Summary: The investment landscape for Johnson & Johnson (JNJ) appears fraught with challenges, as technical indicators on the monthly chart convey a narrative of heightened caution. A synthesis of volume data, oscillator behavior, and cloud-based resistance delineates a precarious pathway for the equity. Amid the backdrop of an imminent earnings report, our technical scrutiny attempts to extrapolate JNJ's potential market trajectory with speculative price targets, enriching the strategic arsenal of the discerning investor. Technical Examination: JNJ's price action is ensconced within a pivotal junction, as evidenced by the candlesticks' interaction with the Ichimoku Cloud and the Fibonacci retracement levels. The recent close below the 0.618 Fib level (171.75) undermines bullish fortitude, while the cloud’s senkou span A (160.46) looms overhead as a formidable deterrent to upward mobility. Ichimoku Cloud Analysis: The cloud's forward projection signals a redoubtable resistance zone, with senkou span B (165.82) reinforcing the ceiling. The Tenkan-sen (147.60) beneath the Kijun-sen (163.14) augurs for continued caution, as the lagging span flirts with price candles from 26 periods prior, suggesting latent bearish sentiment. Relative Strength Index (RSI): JNJ's RSI presents a demure posture at 41.88, a liminal state neither entrenched in bullish territory nor capitulating to bearish dominion. Such neutrality belies the latent potential for a decisive move, contingent upon catalysts from the forthcoming earnings discourse. Moving Average Convergence Divergence (MACD): The MACD chronicles a tale of bearish momentum, as the MACD line (-1.21) diverges from the signal line (-2.32), albeit with diminishing bearish histogram bars. This could intimate a forthcoming attenuation of downward pressure or a pause in bearish continuation. On-Balance Volume (OBV): The OBV metric at 9.318B exhibits a steady trend, lacking significant impetus. This volume-based indicator's plateau suggests a market in equilibrium, with neither buyers nor sellers achieving a clear victory in volume dominance. Market Context and Speculative Price Forecasts: The strategic positioning of JNJ ahead of its earnings report is akin to a game of high-stakes poker. With an average volume (30D) of 6.75M and a market capitalization of $356.5B, JNJ’s beta of 0.54 insinuates lower volatility relative to the broader market. Dividend yield at 3.20% continues to be a linchpin for yield-seeking investors. Given the confluence of technicals, a breach below the current Tenkan-sen level could cascade into a test of the 145.00 USD support echelon, with a speculative target near the 140.00 USD fulcrum if bearish sentiment crystallizes post-earnings. Conversely, should the earnings report provide a catalyst for a bullish reversal, an assault on the 150.00 USD level may ensue, with the cloud's senkou span acting as the next battleground for bulls. Closing Thoughts: In the looming shadow of JNJ's earnings report, the amalgamation of technical signals leans towards a bearish bias, tempered by the potential for a shift in sentiment. Market participants would do well to monitor volume flows and price action post-earnings, with a tactical eye on the RSI and MACD for early indications of momentum shifts. Investors are reminded that technical analysis is not infallible and must be integrated with a robust risk management strategy. Disclaimer: This technical analysis is for informational purposes only and does not constitute investment advice. Traders and investors should perform their own due diligence and consider their risk tolerance before engaging in the market. Past performance is not indicative of future returns, and the speculative nature of price targets should be approached with caution.
NYSE:JNJ
by AxiomEx
Yes, There's a lot to unpack:Earnings Outlook: Analysts are projecting earnings of $2.64 per share, a slight dip of 1.5% compared to the previous year and with revenues estimated to be around $21.38 billion, marking a 13.6% decrease year-over-year, there are certainly some intriguing dynamics at play. ------------------------------------------------------------------------------------- I'm not one to make predictions without the full picture, so I'll be holding off on sharing my analysis until after the earnings report is out. Once I've had a chance to dissect the numbers and assess the implications for Johnson & Johnson's future trajectory, you can expect a detailed breakdown from me. My post-earnings analysis will be in the updates on this idea, I will explore what the numbers mean for investors and whether Johnson & Johnson is poised for growth or facing challenges ahead.
NYSE:JNJ
by una_exp
JNJ @ $151Looking at NYSE:JNJ and i realise that the pattern has activated this is one stock unfortunately am going to miss out on the entry but am going to share it with you am currently trading FX_IDC:EURUSD because of the jobs report coming out this Friday this one showed up on my strategy screen so instead of letting it go to waste I thought i share it with you instead so that you can learn from this pattern it follows the rocket booster strategy now you may be thinking, "What is the rocket booster strategy?" let me show you: Price has to be Below the 50 EMA Price has to be below the 200 EMA The 50 EMA should cross below the 200 EMA Now the question is will this stock gap on earnings within the next two weeks? i don't know but I have gotten an early alert if I still see an entry on this stock next week am going to enter it Hopefully, it will gap down on the earnings report by then Thank you for reading Rocket boost this content to learn more. Disclaimer: This is not financial advice you will lose money from trading learn risk management take this as a warning.
NYSE:JNJShort
by lubosi
JNJ has bottomed and can rise by +50%Johnson & Johnson gives a very clear idea of its trend on the 1M timeframe. The price may be under the 1D MA50 but has reached the bottom of the multi year Channel Up that started at the bottom of the 2008-2009 crisis. Being neutral on the 1M technical outlook (RSI = 45.714, MACD = -1.180, ADX = 20.525) has historically been one of the best buy opportunities, in fact the stock has grown by at least +53.04% three time during that time span. We shouldn't also ignore the fact that the 1M MA100 is still holding and has been doing so since June 2012. We are aiming long term for at least +53.04% again (TP = 220.00). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:JNJLong
by InvestingScope
JOHNSON & JOHNSON More pain along the way. SELL.Johnson & Johnson (JNJ) got rejected on its 1D MA200 (orange trend-line) - 1D MA50 (blue trend-line) Resistance Zone. It has been practically trading sideways since the start of the year and based on the Sine Waves, that priced the new Top (Lower Highs trend-line) of the 2-year Channel Down pattern. The expected completion of a Bearish Cross this week on the 1W RSI, will confirm the Sell Signal, as all 3 previous Bearish Cross sequences were forme just after a Top. Though their declines ranged from -17.58% to -14.78%, we will use the October 10 2022 Low as an example and target the 0.9 Fibonacci retracement level at 147.00 as since the Bullish Leg was limited, we expect an equally less aggressive Bearish Leg towards the bottom of the Sine Waves. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:JNJShort
by TradingShot